Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

DNA methylation and stroke prognosis, an epigenome-wide association study

  • Jiménez-Balado, Joan|||0000-0003-4125-9134
  • Fernandez-Perez, Isabel|||0000-0002-9949-1393
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Lazcano, Uxue|||0000-0003-3948-3372
  • Soriano Tárraga, Carolina|||0000-0002-5635-273X
  • Vallverdú-Prats, Marta|||0000-0002-5262-817X
  • Mola-Caminal, Marina
  • Rey-Álvarez, Lucía|||0000-0003-3000-4814
  • Macias Gómez, Adrià|||0000-0003-0926-681X
  • Suárez-Pérez, Antoni|||0000-0002-0832-7580
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • Rodriguez Campello, Ana Maria|||0000-0001-8621-1420
  • Cuadrado Godia, Elisa|||0000-0002-9147-875X
  • Ois, Angel|||0000-0002-1375-5950
  • Esteller, M.|||0000-0003-4490-6093
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
Background and aims: Stroke is the leading cause of adult-onset disability. Although clinical factors influence stroke outcome, there is a significant variability among individuals that may be attributed to genetics and epigenetics, including DNA methylation (DNAm). We aimed to study the association between DNAm and stroke prognosis. Methods and results: To that aim, we conducted a two-phase study (discovery-replication and meta-analysis) in Caucasian patients with ischemic stroke from two independent centers (BasicMar [discovery, N = 316] and St. Pau [replication, N = 92]). Functional outcome was assessed using the modified Rankin Scale (mRS) at three months after stroke, being poor outcome defined as mRS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Interaction of Sex and Diabetes on Outcome After Ischemic Stroke

  • Soriano-Reixach, Maria Montserrat
  • Vivanco-Hidalgo, Rosa Maria|||0000-0001-7547-0291
  • Ois, Angel|||0000-0002-1375-5950
  • Rodriguez Campello, Ana Maria|||0000-0001-8621-1420
  • Roquer González, Jaume|||0000-0001-5992-2606
The relationship between ischemic stroke (IS), diabetes mellitus (DM), and sex is intriguing. The aim of this study was to assess the effect modification of sex in the association between DM and short- and long-term disability and mortality in first-ever IS patients. In a retrospective, observational, hospital-based study of a prospective series including first-ever IS patients from January 2006 until July 2011, differences in 3-month and 5-year mortality, and disability between diabetic and non-diabetic patients [modified Rankin Scale (mRS) from 3 to 5] were analyzed by sex. In total, 933 patients (36.3% with DM, 50.5% women) were included. Overall 3-month and 5-year mortality were 150 (16.1%) and 407 (44.1%), respectively. Adjusted for age, previous mRS, and stroke severity, patients with DM had significantly higher 3-month disability [hazard ratio (HR): 1.49 (95% confidence interval (CI): 1.39-1.70), p < 0.0001], 5-year disability [HR: 1.41 (95% CI: 1.07-1.86), p = 0.015], and 5-year mortality [HR: 1.48 (95% CI: 1.20-1.81), p < 0.0001], compared with the non-DM group. Compared with non-DM women, women with diabetes had worse 3-month disability [HR: 1.81 (95% CI: 1.33-2.46), p < 0.0001] and 5-year mortality [HR: 1.72 (95% CI: 1.30-2.20), p < 0.0001], and a trend for 5-year disability [HR: 1.40 (95% CI: 0.99-2.09), p = 0.057]. In men, DM had an effect on 3-month disability [HR: 1.45 (95% CI: 1.07-1.96), p = 0.018], a trend for 5-year disability [HR: 1.43 (95% CI: 0.94-2.19), p = 0.096], but no clear effect on 5-year mortality [HR: 1.22 (95% CI: 0.91-1.65), p = 0.186]. Sex has a modifier effect on mortality in first-ever IS diabetic patients. Long-term mortality is increased in diabetic women compared with non-diabetic women, a difference not observed in men.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sleep/wake cycle alterations as a cause of neurodegenerative diseases, A Mendelian randomization study

  • Cullell, Natalia|||0000-0001-5118-1014
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Amaut, K.E.U.
  • Krupinski, J.
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Sleep and/or wake cycle alterations are common in neurodegenerative diseases (ND). Our aim was to determine whether there is a causal relationship between sleep and/or wake cycle patterns and ND (Parkinson's disease (PD) age at onset (AAO), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS)) using two-sample Mendelian Randomization (MR). We selected 12 sleep traits with available Genome-Wide Association Study (GWAS) to evaluate their causal relationship with the ND risk through Inverse-Variance Weighted regression as main analysis. We used as outcome the latest ND GWAS with available summary-statistics: PD-AAO (N = 17,996), AD (N = 21,235) and ALS (N = 40,136). MR results pointed to a causal effect of subjective and objective-measured morning chronotype on later PD-AAO (95%CI:0.33-1.81, p = 8.47×10 and 95%CI:-7.28 to -4.44, p = 5.87×10, respectively). Sleep efficiency was causally associated with a decreased AD risk (95%CI:-20.408 to -0.66, p = 0.04) and daytime sleepiness with an increased ALS risk (95%CI:0.15 to 1.61, p = 0.01). Our study suggests that sleep and/or wake patterns have causal relationship with ND. Given that sleep and/or wake patterns are modifiable risk factors, sleep interventions should be investigated as a potential treatment in PD-AAO, AD and ALS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain

  • Cullell, Natalia|||0000-0001-5118-1014
  • Carrera, Caty|||0000-0002-0804-0969
  • Muiño, Elena|||0000-0001-5839-7328
  • Torres-Aguila, Nuria|||0000-0002-9502-9310
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • González-Sánchez, Jonathan
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Molina, Jessica
  • Besora, Sarah
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • Buongiorno, María-Teresa
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • de Torres-Chacón, Reyes
  • Montaner, Joan|||0000-0003-4845-2279
  • Mancha, Fernando|||0000-0003-0310-0894
  • Cabezas, Juan Antonio
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Purroy, Francisco|||0000-0002-1808-5968
  • Cambray, Serafi
  • Freijo, María del Mar
  • Vives-Bauzá, Cristòfol|||0000-0001-5735-8335
  • Tur, Silvia
  • Font, Maria-Àngels
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Obach, Víctor|||0000-0002-0518-1053
  • Calleja, Ana
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Rodríguez-Yáñez, Manuel
  • Castillo, José
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Krupinski, Jerzy|||0000-0002-5136-8898
Acenocoumarol is an oral anticoagulant with significant interindividual dose variations. Variants in CYP2C9 and VKORC1 have been associated with acenocoumarol maintenance dose. We analysed whether any of the 49 polymorphisms in CYP2C9 and VKORC1 previously associated with acenocoumarol maintenance dose in a Genome-Wide Association study (GWAs) in Dutch population are associated with stroke recurrence, intracranial haemorrhage (ICH) and acenocoumarol maintenance dose in a Spanish population. We performed a GWAs using Human Core Exome-chip (Illumina) in 78 patients stroke patients treated with acenocoumarol for secondary prevention enrolled as part of the prospective investigator-initiated study (IIS) SEDMAN Study. Patients were followed-up a median of 12.8 months. Three and eight patients had recurrent stroke and ICH events, respectively. We found 14 of the 49 published variants associated with acenocoumarol maintenance dose (p < 0.05). Six polymorphisms were associated with stroke recurrence and four variants with ICH (p < 0.05). In conclusion, variants in VKORC1 and CYP2C9 are associated with acenocoumarol maintenance dose, stroke recurrence and ICH in a Spanish cohort. These results highlight the relevance of studying pharmacogenetics associated with efficacy and safety of anticoagulant drugs and justify studies with larger sample size and different ethnic populations.